Literature DB >> 2472774

Reverse transcriptases from human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus (SIVMAC) are susceptible to inhibition by foscarnet and 3'-azido-3'-deoxythymidine triphosphate.

L Vrang1, B Oberg, J Löwer, R Kurth.   

Abstract

Reverse transcriptases from human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus (SIV) were investigated with respect to susceptibilities to the reverse transcriptase inhibitors foscarnet and 3'-azido-3'-deoxythymidine triphosphate (AZTTP). The different reverse transcriptases had the same sensitivity to foscarnet (50% inhibition at 0.10 to 0.16 microM). The Ki values for AZTTP were 0.01 to 0.02 microM for HIV-1 reverse transcriptase and 0.02 to 0.03 microM for HIV-2 and SIVMAC reverse transcriptases.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2472774      PMCID: PMC175960          DOI: 10.1128/AAC.32.11.1733

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  Origins of HTLV-4.

Authors:  R C Desrosiers; M D Daniel; N L Letvin; N W King; R D Hunt
Journal:  Nature       Date:  1987 May 14-20       Impact factor: 49.962

2.  Isolation of a new human retrovirus from West African patients with AIDS.

Authors:  F Clavel; D Guétard; F Brun-Vézinet; S Chamaret; M A Rey; M O Santos-Ferreira; A G Laurent; C Dauguet; C Katlama; C Rouzioux
Journal:  Science       Date:  1986-07-18       Impact factor: 47.728

3.  PPi analogs as inhibitors of human T-lymphotropic virus type III reverse transcriptase.

Authors:  L Vrang; B Oberg
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

4.  Inhibition of the reverse transcriptase from HIV by 3'-azido-3'-deoxythymidine triphosphate and its threo analogue.

Authors:  L Vrang; H Bazin; G Remaud; J Chattopadhyaya; B Oberg
Journal:  Antiviral Res       Date:  1987-03       Impact factor: 5.970

5.  Variation among the human T-cell lymphotropic virus type III (HTLV-III/LAV) strains.

Authors:  R Patarca; W A Haseltine
Journal:  J Theor Biol       Date:  1987-03-21       Impact factor: 2.691

6.  Molecular cloning and polymorphism of the human immune deficiency virus type 2.

Authors:  F Clavel; M Guyader; D Guétard; M Sallé; L Montagnier; M Alizon
Journal:  Nature       Date:  1986 Dec 18-31       Impact factor: 49.962

7.  3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.

Authors:  H Mitsuya; K J Weinhold; P A Furman; M H St Clair; S N Lehrman; R C Gallo; D Bolognesi; D W Barry; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1985-10       Impact factor: 11.205

8.  Dideoxynucleosides are less inhibitory in vitro against human immunodeficiency virus type 2 (HIV-2) than against HIV-1.

Authors:  D D Richman
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

9.  Functional purification and enzymic characterization of the RNA-dependent DNA polymerase of human immunodeficiency virus.

Authors:  E M Wondrak; J Löwer; R Kurth
Journal:  J Gen Virol       Date:  1986-12       Impact factor: 3.891

10.  Human immunodeficiency virus reverse transcriptase. General properties and its interactions with nucleoside triphosphate analogs.

Authors:  Y C Cheng; G E Dutschman; K F Bastow; M G Sarngadharan; R Y Ting
Journal:  J Biol Chem       Date:  1987-02-15       Impact factor: 5.157

View more
  8 in total

Review 1.  Antiretroviral drug resistance in human immunodeficiency virus type 2.

Authors:  Michel L Ntemgwa; Thomas d'Aquin Toni; Bluma G Brenner; Ricardo J Camacho; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2009-05-26       Impact factor: 5.191

Review 2.  Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis.

Authors:  P Chrisp; S P Clissold
Journal:  Drugs       Date:  1991-01       Impact factor: 9.546

3.  Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase.

Authors:  M Baba; E De Clercq; H Tanaka; M Ubasawa; H Takashima; K Sekiya; I Nitta; K Umezu; H Nakashima; S Mori
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

Review 4.  Antiviral therapy in human immunodeficiency virus infections. Current status (Part II).

Authors:  E Sandström; B Oberg
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

Review 5.  Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives.

Authors:  J Balzarini
Journal:  Pharm World Sci       Date:  1994-04-15

6.  Human immunodeficiency virus types 1 and 2 exhibit comparable sensitivities to Zidovudine and other nucleoside analog inhibitors in vitro.

Authors:  Robert A Smith; Geoffrey S Gottlieb; Donovan J Anderson; Crystal L Pyrak; Bradley D Preston
Journal:  Antimicrob Agents Chemother       Date:  2007-10-29       Impact factor: 5.191

7.  Phosphorylation of 3'-azido-2',3'-dideoxyuridine and preferential inhibition of human and simian immunodeficiency virus reverse transcriptases by its 5'-triphosphate.

Authors:  B F Eriksson; C K Chu; R F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

Review 8.  Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.

Authors:  A J Wagstaff; H M Bryson
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.